Bibliografia

1. https://www.epicentro.iss.it/epatite/epidemiologia-mondo diseases, in Cochrane database of systematic reviews (Online), nº 4, 17 ottobre 2007.
2. Eriksson S., Eriksson KF., Bondesson L. Nonalcoholic steatohepatitis obesity: a reversible condition. Acta Med Scand 220,1986
3. R. Marzocchi, C. Zannoni, S. Moscatiello, G. Marchesini. La steatosi epatica non alcolica: una patologia emergente di interesse metabolico.
4. Heidelbaugh JJ., Bruderly M. Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation. Am Fam Physician. 2006;74(5):756-762
5. National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002.
6. Adinolfi LE., Gambardella M., Andreana A. et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlate with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364
7. A. Rambaldi, Jacobs BP., Gluud C., Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases, in Cochrane database of systematic reviews (Online), nº 4, 17 ottobre 2007.
8. Bhagavan HN., Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53.
9. LaBrecque D. et al. World Gastroenterology Organisation Global Guidelines: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology: July 2014-Volume 48-Issue 6-p 467-473. WGO Guideline.
10. Awang D. Milk thistle. Can Pharm J 1993; 422, 403-404.
11. Wagner H. Antihepatotoxic flavonoids. Plant Flavonoids in Biology and medicine. Biochemical, Pharmacological, and Structure-Activity Relationships. 1986; Alan R. Liss, New York, pp. 545-558.
12. Adzet T. Polyphenolic compounds with biological and pharmacological activity. Herbs Spices Med Plants 1986;1,167-184.
13. Valenzuela A. et al. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Medica 1989; 55, 452-22.
14. Milk Thistle herb (Cardui mariae herba). Commission E Monograph. http://buecher.heilpflanzen-welt.de/BGA-Commission-E-Monographs/0252.htm)
15. Hajaghamohammadi A., Ziaee A., Rafiei R. The Efficacy of Silymarin in Decreasing Transaminase Activities in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. Hepatitis Monthly Sett. 2008
16. Select Committee on GRAS Substances (SCOGS) Opinion: L-ascorbic acid (http://www.fda.gov/food/ingredientspackaginglabeling/gras/scogs/ucm260452.htm)
17. Stephen A. Harrison, Sigurd Torgerson, Paul Hayashi et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. The American Journal of Gastroenterology (2003).
18. Clarke MW., Burnett JR., Croft KD. Vitamin E in human health and disease. Crit Rev Clin Lab Sci.2008;45:417-50.
19. Select Committee on GRAS Substances (SCOGS) Opinion: alpha-Tocopherol acetate,Tocopherols. (http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260987.htm)
20. T. Hasegawa, M. Yoneda, K. Nakamura, I. Makino, A. Terano. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Alimentary Pharmacology & Therapeutics. 2001
21. Aller R., Izaola O., Gómez S., Tafur C., González G. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015 Aug.
22. Tarozzi “Ruolo fisiologico degli acidi grassi polinsaturi” (Skepsis I,1-1999.20-37).
23. Schrauzer GN. The nutritional significance, metabolism and toxicology of selenomethionine.Adv Food Nutr Res. 2003;47:73-112
24. Ales Vidlara, Jitka Vostalovab, Jitka Ulrichovab et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy-a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Sep
25. Bhagavan HN., Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53
26. Farsi F., Mohammadshahi M., Alavinejad P. et al. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr. 2015 Jul 9.